$0.36
0.39% day before yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US09077B1044
Symbol
BCAB

BioAtla Inc Stock price

$0.36
+0.01 4.37% 1M
-0.02 6.31% 6M
-0.24 39.75% YTD
-1.44 80.21% 1Y
-8.62 96.03% 3Y
-17.64 98.02% 5Y
-17.64 98.02% 10Y
-17.64 98.02% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
-0.00 0.39%
ISIN
US09077B1044
Symbol
BCAB
Industry

Key metrics

Basic
Market capitalization
$20.9m
Enterprise Value
$2.7m
Net debt
positive
Cash
$18.2m
Shares outstanding
58.7m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
27.2%
Return on Equity
-489.1%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-112.2m
EBIT
- | $-68.6m
Net Income
- | $-77.1m
Free Cash Flow
$-52.3m
Growth (TTM | estimate)
Revenue
- | -100.0%
EBITDA
- | -53.7%
EBIT
- | 7.2%
Net Income
- | -10.5%
Free Cash Flow
51.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-0.9
Short interest
7.5%
Employees
61
Rev per Employee
$180.0k
Show more

Is BioAtla Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

BioAtla Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a BioAtla Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a BioAtla Inc forecast:

Buy
80%
Hold
20%

Financial data from BioAtla Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
11 11
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
16% 16%
199%
- Research and Development Expense 63 63
39% 39%
574%
-73 -73
43% 43%
-664%
- Depreciation and Amortization 0.93 0.93
24% 24%
8%
EBIT (Operating Income) EBIT -74 -74
43% 43%
-672%
Net Profit -70 -70
43% 43%
-634%

In millions USD.

Don't miss a Thing! We will send you all news about BioAtla Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioAtla Inc Stock News

Neutral
Seeking Alpha
15 days ago
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 AM ET Company Participants Eric L. Sievers - Chief Medical Officer Jay M.
Neutral
The Motley Fool
17 days ago
BioAtla (BCAB) Q2 Loss Narrows 27%
Neutral
GlobeNewsWire
17 days ago
CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; meeting planned with U.S. Food & Drug Administration (FDA) in 3Q 2025 to discuss proposed Phase 3 study design Company is advancing partnerin...
More BioAtla Inc News

Company Profile

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Jay Short
Employees 61
Founded 2007
Website www.bioatla.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today